Strategic implications for investors and industrials

Sequencing Trends Worth Watching: Commercial Potential of Technology Demands that Industry and Investors Alike Stay Up to Date

Scientia Advisors' associate, Brian Clancy, and managing partner, Harry Glorikian, are featured in the September 1st, 2011 issue of Genetic Engineering & Biotechnology News with an article titled:"Sequencing Trends Worth Watching: Commercial Potential of Technology Demands that Industry and Investors Alike Stay Up to Date."

Scientia Advisors does a great deal of thinking about the evolution of sequencing technology, its commercial potential, and the strategic implications for stakeholders. In this article, the authors outline, define, and describe some of the more forward looking trends the company is following, including sequencing activity polarization, workflow value shifts, and clinical and commercial applications.

The article can be accessed on the Genetic Engineering & Biotechnology News website here.

SCIENTIA ADVISORS, LLC | info@scientiaadv.com

55 Cambridge Parkway, Suite 300E, Cambridge MA 02142 | Phone: 617-299-3000 | Fax: 617-812-0315